Revolution Medicines, Inc. (RVMD)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$4.32B
Stockholders' Equity
$2.61B
Cash & Equivalents
$815.4M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Revolution Medicines, Inc. reported net income of -$644.4M and total assets of $4.32B. Every figure below is taken directly from Revolution Medicines, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2018–FY2025 · as reported

$50.0M-$540.6M-$1.13B
FY2018FY2020FY2022FY2024FY2025
Revenue$0Net income-$1.13B
FY2018 revenue
$20.2M
FY2025 revenue
$0

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$0-$1.13B
FY2024$0-$600.1M
FY2023$11.6M-$436.4M
FY2022$35.4M-$248.7M
FY2021$29.4M-$187.1M
FY2020$43.0M-$108.2M
FY2019$50.0M-$47.7M
FY2018$20.2M-$41.8M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 13, 2026on EDGAR ↗
8-KSep 1, 2026on EDGAR ↗
8-KAug 26, 2026on EDGAR ↗
8-KAug 5, 2026on EDGAR ↗
10-QAug 5, 2026on EDGAR ↗
8-KJun 22, 2026on EDGAR ↗
8-KMay 6, 2026on EDGAR ↗
10-QMay 6, 2026on EDGAR ↗
DEF 14AApr 27, 2026on EDGAR ↗
8-KApr 17, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$4.32Bsource ↗
Stockholders’ Equity$2.61Bsource ↗
Cash & Equivalents$815.4Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$644.4Msource ↗
Operating Income-$505.1Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$394.9Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-3.06source ↗
EPS (basic)$-3.06source ↗
Shares Outstanding214.3Msource ↗
Cash from Operations-$387.3Msource ↗
Cash from Financing$2.42Bsource ↗
Cash from Investing-$1.66Bsource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
110
Net shares
-535.4K

Restatement history

Point-in-time

No material restatements detected across 199 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches RVMD’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RVMD

MCP tool: get_sec_fundamentals ticker=RVMD

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RVMD/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=RVMD as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/RVMD/history

MCP tool: get_fundamentals_history ticker=RVMD

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/RVMD

MCP tool: get_financial_health ticker=RVMD

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.